The current treatment options for chronic kidney disease in patients with type 2 diabetes is discussed by Professor Hiddo Heerspink (University Medical Center Groningen, Groningen, Netherlands). Also discussed is the mechanism of tirzepatide, a novel once-weekly medication, which has shown to improve kidney outcomes in adults with type 2 diabetes who have increased cardiovascular risk.
Professor Hiddo Heerspink presented an abstract entitled ‘Effects of Tirzepatide vs. Insulin Glargine 100 U/mL on Kidney Outcomes in Participants with Type 2 Diabetes in SURPASS-4‘ at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
- Why is it so important to control the progression of chronic kidney disease (CKD) in people with type 2 diabetes? (0:22)
- Despite current treatment options, what unmet needs exist in the effective management of CKD in people with type 2 diabetes? (0:59)
- What is the mechanism of action of tirzepatide, and how does this differ from currently available therapies in this indication? (1:50)
Disclosures: Hiddo Heerspink is a consultant for: AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli Lilly, Janssen, NovoNordisk and Travere. Hiddo Heerspink has received grant/research support from AstraZeneca, Boehringer Ingelheim and Novo Nordisk and is a speaker’s bureau participant with AstraZeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
Share this Video
Related Videos In Chronic Kidney Disease
Jennifer Green, EASD 2022: Combination effect of finerenone and empagliflozin in participants with chronic kidney disease and type 2 diabetes: The CONFIDENCE Study
Finerenone (a selective nonsteroidal mineralocorticoid receptor antagonist) and the SGLT2 inhibitor empagliflozin may reduce both kidney and cardiovascular risks in people with chronic kidney disease and type 2 diabetes. It is unknown whether dual therapy with finerenone and empagliflozin is superior to either agent alone. In this touchENDOCRINOLOGY interview, Prof. Jennifer Green (Duke University School […]
Jennifer Green, EASD 2022: Unmet needs in reducing the risk of chronic kidney disease in people with type 2 diabetes
There is a high unmet need for new treatments to preserve kidney function and delay kidney disease progression in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). In this touchENDOCRINOLOGY interview, Prof. Jennifer Green (Duke University School of Medicine, Durham, NC, USA) discusses the unmet needs in reducing the risk of CKD […]
Peter Rossing, EASD 2022: The effect of semaglutide on risk of MACE by baseline kidney function: SUSTAIN 6 and PIONEER 6 post hoc analysis
SUSTAIN 6 and PIONEER 6 investigated the effects of semaglutide versus placebo on major adverse cardiovascular events (MACE). The current post hoc analysis investigated the association between baseline kidney function and risk of MACE, and the effect of semaglutide on risk of MACE by baseline kidney function. In this touchENDOCRINOLOGY interview, Prof. Peter Rossing (University […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!